Condition: Non-muscle-invasive Bladder Cancer · NMIBC · Non-Muscle Invasive Bladder Carcinoma · Sponsor: Aura Biosciences
The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.
This description comes directly from the study's public registry record.
Medical Monitor · 617-500-8864 · clinical@aurabiosciences.com
Always discuss trial participation with your own doctor first.
| Arkansas Urology | Little Rock, Arkansas, United States | Terminated |
| Tower Urology | Los Angeles, California, United States | Recruiting |
| Saint John's Cancer Institute | Santa Monica, California, United States | Recruiting |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
| Carolina Urologic Research Center | Myrtle Beach, South Carolina, United States | Recruiting |
| Urology Associates, P.C. | Nashville, Tennessee, United States | Suspended |
| Urology Clinics of North Texas | Dallas, Texas, United States | Recruiting |
| Baylor College of Medicine | Houston, Texas, United States | Recruiting |
| The University of Texas San Antonio | San Antonio, Texas, United States | Recruiting |
| Urology San Antonio/USA Clinical Trials | San Antonio, Texas, United States | Recruiting |
| The Urology Place | San Antonio, Texas, United States | Recruiting |
| Westmead Private Hospital | Westmead, New South Wales, Australia | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05483868